PL2176220T3 - Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego - Google Patents

Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego

Info

Publication number
PL2176220T3
PL2176220T3 PL08792430T PL08792430T PL2176220T3 PL 2176220 T3 PL2176220 T3 PL 2176220T3 PL 08792430 T PL08792430 T PL 08792430T PL 08792430 T PL08792430 T PL 08792430T PL 2176220 T3 PL2176220 T3 PL 2176220T3
Authority
PL
Poland
Prior art keywords
pyrrolidin
derivatives
androgen receptor
receptor modulators
modulators
Prior art date
Application number
PL08792430T
Other languages
English (en)
Polish (pl)
Inventor
Atsushi Hasuoka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PL2176220T3 publication Critical patent/PL2176220T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08792430T 2007-08-07 2008-08-06 Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego PL2176220T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19
EP08792430A EP2176220B1 (en) 2007-08-07 2008-08-06 Pyrrolidin-2-one derivatives as androgen receptor modulators
PCT/JP2008/064500 WO2009020234A2 (en) 2007-08-07 2008-08-06 Pyrrolidin-2 -one derivatives as androgen receptor modulator

Publications (1)

Publication Number Publication Date
PL2176220T3 true PL2176220T3 (pl) 2013-08-30

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08792430T PL2176220T3 (pl) 2007-08-07 2008-08-06 Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego

Country Status (34)

Country Link
US (2) US7834051B2 (enExample)
EP (1) EP2176220B1 (enExample)
JP (1) JP5292390B2 (enExample)
KR (1) KR20100049644A (enExample)
CN (1) CN101821235B (enExample)
AR (1) AR067823A1 (enExample)
AU (1) AU2008284662B2 (enExample)
BR (1) BRPI0814957B8 (enExample)
CA (1) CA2695852C (enExample)
CL (1) CL2008002313A1 (enExample)
CO (1) CO6160326A2 (enExample)
CR (1) CR11266A (enExample)
CY (1) CY1114067T1 (enExample)
DK (1) DK2176220T3 (enExample)
DO (1) DOP2010000053A (enExample)
EA (1) EA017429B1 (enExample)
ES (1) ES2406685T3 (enExample)
GE (1) GEP20125571B (enExample)
HR (1) HRP20130374T1 (enExample)
JO (1) JO2864B1 (enExample)
MA (1) MA31639B1 (enExample)
ME (1) ME01579B (enExample)
MX (1) MX2010001484A (enExample)
MY (1) MY159910A (enExample)
NZ (1) NZ583624A (enExample)
PE (1) PE20090899A1 (enExample)
PL (1) PL2176220T3 (enExample)
PT (1) PT2176220E (enExample)
RS (1) RS52812B (enExample)
SI (1) SI2176220T1 (enExample)
TN (1) TN2010000062A1 (enExample)
TW (1) TWI418543B (enExample)
WO (1) WO2009020234A2 (enExample)
ZA (1) ZA201001289B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017429B1 (ru) * 2007-08-07 2012-12-28 Такеда Фармасьютикал Компани Лимитед Циклические аминные соединения
US8268872B2 (en) * 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
AR071069A1 (es) * 2008-03-26 2010-05-26 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
BR112013007685B1 (pt) 2010-09-28 2021-11-09 Radius Pharmaceuticals, Inc Compostos moduladores de receptor andrógeno seletivos, composição farmacêutica compreendendo os referidos compostos, método de identificação de um composto capaz de modular um receptor andrógeno, usos de um composto ou da composição e processo para a preparação de um composto
US20150057452A1 (en) * 2012-04-04 2015-02-26 Catylix, Inc. Selective androgen receptor modulators
CN104768544B (zh) 2012-08-09 2017-06-16 迪纳米斯治疗公司 包括葡甲胺或其盐的组合物在制备减少或预防甘油三酯水平增加的药物中的应用
JP6338583B2 (ja) * 2012-09-21 2018-06-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｃ−ｃ三重結合を有する化合物およびそれらの液晶混合物における使用。
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
KR101597327B1 (ko) 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
JP7221699B2 (ja) 2016-06-22 2023-02-14 エリプセス ファーマ エルティーディー Ａｒ＋乳癌の治療方法
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
EP3908581A1 (en) 2019-01-11 2021-11-17 Grünenthal GmbH Substituted pyrrolidine amides iii
KR20210127961A (ko) 2019-02-12 2021-10-25 래디어스 파마슈티컬스, 인코포레이티드 방법 및 화합물
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
AU754529B2 (en) * 1998-09-22 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
PT1463497E (pt) 2001-12-06 2011-12-20 Gtx Inc Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
US20050101657A1 (en) * 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
US7022870B2 (en) 2002-06-17 2006-04-04 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
KR20050044902A (ko) 2002-08-12 2005-05-13 다케다 야쿠힌 고교 가부시키가이샤 축합 벤젠 유도체 및 용도
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP1747193A1 (en) * 2004-05-11 2007-01-31 Pfizer Products Incorporated Benzonitrile derivatives to treat musculoskeletal frailty
CN101248069A (zh) 2004-05-17 2008-08-20 阿卡蒂亚药品公司 雄激素受体调节剂及用其治疗疾病的方法
AU2005251781C1 (en) 2004-06-07 2008-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
KR20070112775A (ko) 2005-01-10 2007-11-27 아카디아 파마슈티칼스 인코포레이티드 선택적인 안드로겐 수용체 조절자로서의 아미노페닐 유도체
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
JP5089578B2 (ja) 2005-05-13 2012-12-05 イーライ リリー アンド カンパニー 選択的なアンドロゲン受容体調節物質としての置換型ｎ−アリールピロリジン
CA2617256C (en) 2005-08-01 2014-07-15 Takeda Pharmaceutical Company Limited Cyclic amine compound
US20090042857A1 (en) 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
MX2009000714A (es) 2006-07-19 2009-07-27 Osurf Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
CA2658558A1 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
WO2008066117A1 (en) 2006-11-30 2008-06-05 Takeda Pharmaceutical Company Limited Cyclic amine compound
EA017429B1 (ru) 2007-08-07 2012-12-28 Такеда Фармасьютикал Компани Лимитед Циклические аминные соединения

Also Published As

Publication number Publication date
EA017429B1 (ru) 2012-12-28
US8420694B2 (en) 2013-04-16
CY1114067T1 (el) 2016-07-27
CL2008002313A1 (es) 2009-05-15
TW200916439A (en) 2009-04-16
TN2010000062A1 (en) 2011-09-26
CO6160326A2 (es) 2010-05-20
MX2010001484A (es) 2010-03-04
HK1143972A1 (en) 2011-01-21
BRPI0814957B8 (pt) 2021-05-25
RS52812B (sr) 2013-10-31
PE20090899A1 (es) 2009-08-06
EP2176220A2 (en) 2010-04-21
CA2695852C (en) 2017-01-03
CA2695852A1 (en) 2009-02-12
NZ583624A (en) 2012-06-29
SI2176220T1 (sl) 2013-05-31
DOP2010000053A (es) 2010-07-15
PT2176220E (pt) 2013-04-09
CR11266A (es) 2010-03-22
US20090042967A1 (en) 2009-02-12
CN101821235B (zh) 2012-11-14
EA201070246A1 (ru) 2010-08-30
AR067823A1 (es) 2009-10-21
HRP20130374T1 (en) 2013-05-31
KR20100049644A (ko) 2010-05-12
ZA201001289B (en) 2011-04-28
EP2176220B1 (en) 2013-03-27
CN101821235A (zh) 2010-09-01
WO2009020234A2 (en) 2009-02-12
BRPI0814957A2 (pt) 2015-02-03
ES2406685T3 (es) 2013-06-07
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28
MY159910A (en) 2017-02-15
GEP20125571B (en) 2012-07-10
AU2008284662B2 (en) 2013-07-25
JP5292390B2 (ja) 2013-09-18
BRPI0814957B1 (pt) 2019-12-03
DK2176220T3 (da) 2013-06-10
WO2009020234A3 (en) 2009-04-16
AU2008284662A1 (en) 2009-02-12
MA31639B1 (fr) 2010-08-02
US7834051B2 (en) 2010-11-16
JP2010535704A (ja) 2010-11-25
JO2864B1 (en) 2015-03-15
TWI418543B (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
HRP20130374T1 (en) Pyrrolidin-2-one derivatives as androgen receptor modulators
SI2094658T1 (sl) Spojine tetrahidrociklopenta(b)indola kot modulatorji androgenskega receptorja
IL200922A0 (en) 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators
SI2297100T1 (sl) Tetrahidrociklopenta(b)indoli kot modulatorji androgenskega receptorja
SI2262785T1 (sl) Derivati benzofurana kot modulatorji fxr
ZA200807551B (en) Selective androgen receptor modulators
GB0701992D0 (en) Grehlin Receptor Modulators
IL211821A0 (en) The compounds as the estrogen related receptors modulators and the uses thereof
ZA201101707B (en) Novel imidazolidine compounds as androgen receptor modulators
IL218696A0 (en) 2-oxo-1- pyrrolidinyl imidazothiadiazole derivatives
ZA201002268B (en) Benzothiazoles as ghrelin receptor modulators
IL211822A0 (en) The compounds as the estrogen related receptors modulators and the uses thereof
ZA201104069B (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
ZA200806237B (en) Cannibinoid receptor modulators
PL2288612T3 (pl) Modulatory receptora GABAA
GB0811212D0 (en) CB1 Receptor Modulators
ZA200907546B (en) New progesterone receptor modulators
PL1991559T3 (pl) Pochodne oksy-steroidowe jako selektywne modulatory receptora progesteronu
HK1143376A (en) Benzothiazoles as ghrelin receptor modulators
HK1160114A (en) Novel imidazolidine compounds as androgen receptor modulators
GB0813350D0 (en) Cannabinoid receptor modulators
GB0717998D0 (en) Canabinoid receptor modulators
GB0807710D0 (en) Receptor and modulators thereof